Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Trial Profile

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top